UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma
Authors:
- Amedeo De NicolòANAmedeo De Nicolò
- Chiara CarcieriCCChiara Carcieri
- Antonio D’avolioADAntonio D’avolio
- 1 May 2017
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 138, 223-230
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and AdultsDrugs, 2014
- Understanding HIV Compartments and ReservoirsCurrent HIV/AIDS Reports, 2014
- Thirty years of the human immunodeficiency virus epidemic and beyondInternational Journal of Oral Science, 2013
- A validated assay by liquid chromatography–tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patientsJournal of Mass Spectrometry, 2013
- Liquid chromatography‐tandem mass spectrometric assay for the non‐nucleoside reverse transcriptase inhibitor rilpivirine in human plasmaBiomedical Chromatography, 2012
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialThe Lancet, 2012
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksThe Lancet, 2012
- Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Therapeutic drug monitoring in highly active antiretroviral therapyExpert Opinion on Drug Safety, 2010
- Therapeutic drug monitoring in HIV infection: current status and future directionsAIDS, 2002